Literature DB >> 15118286

Neurohumoral profiles in patients with hypertrophic cardiomyopathy: differences to hypertensive left ventricular hypertrophy.

Kazuhide Ogino1, Kazuyoshi Ogura, Toru Kinugawa, Shuichi Osaki, Masahiko Kato, Yoshiyuki Furuse, Yoshiharu Kinugasa, Yoko Tomikura, Osamu Igawa, Ichiro Hisatome, Chiaki Shigemasa.   

Abstract

BACKGROUND: Patients with hypertrophic cardiomyopathy (HCM) or hypertensive heart disease (HHD) have increased concentrations of various neurohumoral factors. Thus, the aim of the present study was to evaluate the differences in the neurohumoral profiles of HCM and HHD. METHODS AND
RESULTS: Plasma concentrations of epinephrine, norepinephrine, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), angiotensin II and endothelin-1 were measured in 40 patients with HCM, 35 with HHD, and 15 controls. Additionally, the concentrations of these neurohumoral factors in the coronary sinus and aortic root were measured in 12 HCM patients and 10 controls. Plasma concentrations of norepinephrine, ANP and BNP were significantly higher in HCM than HHD and controls. In HCM, there was no significant correlation between the left ventricular mass index and any neurohumoral factor. The plasma BNP concentration significantly correlated with left intraventricular pressure gradient in HCM. There were significant differences in the plasma concentrations of ANP and BNP between HCM with and without left ventricular diastolic dysfunction. Transcardiac production of BNP was significantly higher in patients with obstructive HCM than in those with non-obstructive HCM.
CONCLUSIONS: The significant neurohumoral differences between HCM and HHD were the plasma concentrations of norepinephrine, ANP and BNP. In HCM patients, the plasma BNP concentration may reflect the intraventricular pressure gradient and left ventricular diastolic dysfunction whereas the plasma ANP concentration reflects only the left ventricular diastolic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118286     DOI: 10.1253/circj.68.444

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  11 in total

1.  Midregional pro-atrial natriuretic peptide: a novel marker of myocardial fibrosis in patients with hypertrophic cardiomyopathy.

Authors:  Elif Elmas; Christina Doesch; Stephan Fluechter; Miriam Freundt; Christel Weiss; Siegfried Lang; Thorsten Kälsch; Dariush Haghi; Jana Papassotiriou; Jan Kunde; Stefan O Schoenberg; Martin Borggrefe; Theano Papavassiliu
Journal:  Int J Cardiovasc Imaging       Date:  2010-09-26       Impact factor: 2.357

2.  Clinical significance of N-terminal-probrain natriuretic peptide in hypertrophic cardiomyopathy.

Authors:  Georgios K Efthimiadis; Areti Hitoglou-Makedou; Georgios Giannakoulas; Anastasia Mitakidou; Theodoros Karamitsos; Haralambos Karvounis; Sotirios Mochlas; Ioannis Styliadis; Haris Stefanidis; Georgios Parcharidis; Georgios Louridas
Journal:  Heart Vessels       Date:  2007-09-20       Impact factor: 2.037

3.  Left Ventricular Hypertrophy in Rhesus Macaques (Macaca mulatta) at the California National Primate Research Center (1992-2014).

Authors:  J Rachel Reader; Don R Canfield; Jennifer F Lane; Sreetharan Kanthaswamy; Amir Ardeshir; A Mark Allen; Ross P Tarara
Journal:  Comp Med       Date:  2016-04       Impact factor: 0.982

4.  Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction.

Authors:  Seon Woon Kim; Seung Woo Park; Seong-Hoon Lim; Sung Uk Kwon; Yu Jeong Choi; Man Ki Park; Sang-Chol Lee; Sang Hoon Lee; Jeong Euy Park; Eun-Seok Jeon
Journal:  Clin Cardiol       Date:  2006-04       Impact factor: 2.882

5.  Quantification and significance of diffuse myocardial fibrosis and diastolic dysfunction in childhood hypertrophic cardiomyopathy.

Authors:  Tarique Hussain; Andreea Dragulescu; Lee Benson; Shi-Joon Yoo; Howard Meng; Jonathan Windram; Derek Wong; Andreas Greiser; Mark Friedberg; Luc Mertens; Michael Seed; Andrew Redington; Lars Grosse-Wortmann
Journal:  Pediatr Cardiol       Date:  2015-01-21       Impact factor: 1.655

6.  Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts.

Authors:  Shinsuke Hanatani; Yasuhiro Izumiya; Seiji Takashio; Sunao Kojima; Megumi Yamamuro; Satoshi Araki; Taku Rokutanda; Kenichi Tsujita; Eiichiro Yamamoto; Tomoko Tanaka; Shinji Tayama; Koichi Kaikita; Seiji Hokimoto; Seigo Sugiyama; Hisao Ogawa
Journal:  Heart Vessels       Date:  2013-03-23       Impact factor: 2.037

7.  Mimics of Hypertrophic Cardiomyopathy - Diagnostic Clues to Aid Early Identification of Phenocopies.

Authors:  Rajiv Sankaranarayanan; Eleanor J Fleming; Clifford J Garratt
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-04

8.  Prevalence of isolated atrial amyloidosis in young patients affected by congestive heart failure.

Authors:  Lia Millucci; Lorenzo Ghezzi; Giulia Bernardini; Daniela Braconi; Piero Tanganelli; Annalisa Santucci
Journal:  ScientificWorldJournal       Date:  2012-03-12

9.  High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease.

Authors:  Nora Seydelmann; Dan Liu; Johannes Krämer; Christiane Drechsler; Kai Hu; Peter Nordbeck; Andreas Schneider; Stefan Störk; Bart Bijnens; Georg Ertl; Christoph Wanner; Frank Weidemann
Journal:  J Am Heart Assoc       Date:  2016-05-31       Impact factor: 5.501

10.  Total Clinical Course and Autopsy Findings of Left Ventricular Outflow Tract Obstruction Due to Sigmoid Septum: Histologically Proven Isolated Basal Septal Hypertrophy.

Authors:  Keisuke Kawai; Hiroyuki Sengoku; Hiroyuki Ishihara; Tomotoshi Akematsu; Masakazu Nanahoshi; Hirotoshi Hariki; Minoru Hasokawa; Ken-Ichi Hirata; Hiroshi Yamabe
Journal:  Intern Med       Date:  2017-08-01       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.